XTLB 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October, 2025

Commission File Number: 001-36000

XTL BiopharmaceuticalsLtd.

(Translation of registrant’s name into English)

26 Ben-Gurion St.

Ramat Gan

5112001 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. (the “Company”) due to personal reasons. Mr. Turjeman’s resignation was not the result of any disagreement with the Company or its management. Noam Band, the Company Chief Executive Officer, was appointed to serve as a member of the Board of Directors in his place, effective immediately.

About XTL Biopharmaceuticals Ltd. (XTL)

XTL is an IP portfolio company. The Company holds 100% of the share capital of The Social Proxy Ltd., a web data company and has sublicensed out an IP portfolio surrounding hCDR1 for the treatment of Lupus disease (SLE).

XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).

For further information, please contact:

Investor Relations, XTL BiopharmaceuticalsLtd.

Tel: +972 3 611 6666

Email: [email protected]

www.xtlbio.com

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

2